Abstract: Presented are an automatic design device for XR-based MEP facilities, and a method therefor, the device comprising: a position calibration unit for calibrating, to the current position of the automatic design device for XR-based MEP facilities in 3D construction site structure data, coordinates corresponding to a preset location in 3D construction site structure data including structure and coordinate information about a construction site, if the automatic design device for XR-based MEP facilities is located at the preset location of the construction site; and a location-tracking unit for tracking the location of the automatic design device for XR-based MEP facilities in the 3D construction site structure data on the basis of the current location when a user wearing the automatic design device for XR-based MEP facilities moves.

Abstract: A coating composition includes a compound of Chemical Formula 1: wherein the groups are described herein.

Abstract: The present disclosure is the first to identify a host cell protein and its function with which MPT63 and MPT64, secreted antigens of Mycobacterium tuberculosis, interact, and to construct a recombinant MPT protein including each domain of MPT63 and MPT64 interacting with the host cell protein, and the recombinant MPT protein may be applied to a use for the prevention and treatment of tuberculosis by confirming that the recombinant MPT protein targets the Mycobacterium tuberculosis-infected macrophages and increases the ROS level and inflammatory cytokine expression in macrophages, thereby inducing the death of Mycobacterium tuberculosis. And MPT protein of the present disclosure can improve the vaccine effect by the BCG vaccine so that it can be used as a tuberculosis vaccine and/or vaccine adjuvant either alone or together with known tuberculosis vaccines.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer, a radiosensitizer composition for treating cancer, and a health functional food for preventing or improving cancer, which comprise N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl) benzamide, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition comprising N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl) benzamide or a derivative thereof as an active ingredient according to the present invention arrests the mitosis of cancer cells to prevent proliferation and at the same time, to exhibit low toxicity in normal cell lines and induce apoptosis only in cancer cell lines, so it can be used as an effective anticancer agent. In addition, the N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl) benzamide of the present invention can increase the sensitivity of the treated cancer cells to radiation, so it can be used as a radiosensitizer composition for cancer treatment.

Abstract: The present invention relates to a pharmaceutical composition and a health functional food composition for preventing, alleviating or treating inflammatory diseases, including Toxoplasma gondii GRA9 protein or a gene encoding the protein as an active ingredient. The present inventors have identified the C-terminal region essential for the NLRP3-mediated mechanism of action and function of Toxoplasma gondii GRA9 in macrophages, which are host immune cells and confirmed the substantial anti-inflammatory and antibacterial effects and the antiseptic effect in vivo. Accordingly, Toxoplasma gondii GRA9 protein or a gene encoding the protein is expected to be usefully utilized in the field of prevention or treatment of inflammatory diseases caused by an abnormal NLRP3-mediated inflammatory response, including sepsis.

Abstract: The present invention relates to a composition for preventing or treating cancer, containing a novel trifluoromethyl phenyl pyrazole derivative as an active ingredient, and, more specifically, to a composition for preventing, alleviating or treating cancer and a radiosensitizer composition for treating cancer with radiotherapy, which contain, as an active ingredient, a novel sulfonamide derivative including N,N-dimethyl-N?-(3-(1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)phenyl)azanesulfonamide. Novel sulfonamide derivatives according to the present invention have an excellent apoptotic effect on cancer cells, and thus are usable as an effective anti-cancer agent, and reduce the radioresistance of cancer cells, and thus can be used as a radiosensitizer composition during cancer treatment.

Abstract: The present disclosure is the first to identify a host cell protein and its function with which MPT63 and MPT64, secreted antigens of Mycobacterium tuberculosis, interact, and to construct a recombinant MPT protein including each domain of MPT63 and MPT64 interacting with the host cell protein, and the recombinant MPT protein may be applied to a use for the prevention and treatment of tuberculosis by confirming that the recombinant MPT protein targets the Mycobacterium tuberculosis-infected macrophages and increases the ROS level and inflammatory cytokine expression in macrophages, thereby inducing the death of Mycobacterium tuberculosis. And MPT protein of the present disclosure can improve the vaccine effect by the BCG vaccine so that it can be used as a tuberculosis vaccine and/or vaccine adjuvant either alone or together with known tuberculosis vaccines.

Abstract: The present invention relates to a novel Toxoplasma gondii GRA8-derived recombinant peptide, and a pharmaceutical composition and functional food for preventing or treating cancer, which includes the same as an active ingredient. The Toxoplasma gondii GRA8-derived recombinant peptide according to the present invention is a novel recombinant peptide in which a specific mitochondrial targeting sequence and an ATP5A1/SIRT3 sequence of GRA8 are conjugated to an acidity-triggered rational membrane (ATRAM), and has considerably improved efficacy in which an inhibitory concentration 50 (IC50) is improved up to 200-fold (in vitro) or 500-fold (in vivo), compared with a conventional GRA8-derived peptide (rGRA8). In addition, since the peptide treatment shows a notably distinct therapeutic effect in mouse models with cancer, the peptide may be effectively used in a pharmaceutical composition or functional food for preventing or treating cancer.

Abstract: The present invention relates to a pharmaceutical composition and a health functional food composition for preventing, alleviating or treating inflammatory diseases, including Toxoplasma gondii GRA9 protein or a gene encoding the protein as an active ingredient. The present inventors have identified the C-terminal region essential for the NLRP3-mediated mechanism of action and function of Toxoplasma gondii GRA9 in macrophages, which are host immune cells and confirmed the substantial anti-inflammatory and antibacterial effects and the antiseptic effect in vivo. Accordingly, Toxoplasma gondii GRA9 protein or a gene encoding the protein is expected to be usefully utilized in the field of prevention or treatment of inflammatory diseases caused by an abnormal NLRP3-mediated inflammatory response, including sepsis.

Abstract: A coating composition includes a compound of Chemical Formula 1: wherein the groups are described herein.

Abstract: An organic light emitting display device includes a display panel including a plurality of pixels each including an organic light emitting diode, a gate driver configured to supply a gate driving signal to each of the pixels, a data driver configured to supply a data voltage to each of the pixels, a multiplexer being switched in response to an external control signal to output any one of the data voltage and a voltage supplied from a separate power supply line, and a timing controller configured to control the multiplexer to transfer the data voltage to a data line of each of the pixels in a refresh period in a low-speed driving mode and transfer the voltage from the separate power supply line to the data line of each of the pixels for at least one anode reset period in a hold period in the low-speed driving mode.

Abstract: The present disclosure relates to a pixel circuit and a display device using the same. The pixel circuit includes a first switch element configured to connect a first node to a third node in a sampling step, a second switch element configured to supply a data voltage to a second node in the sampling step, a third switch element configured to supply a pixel driving voltage to the second node in a emission step after the sampling step, a fourth switch element configured to connect the third node to an anode of a light-emitting element in the emission step, a first capacitor connected to the first node, a second capacitor connected between the third node and the anode of the light-emitting element, and a third capacitor connected between the anode and the cathode of the light-emitting element.

Abstract: The present disclosure relates to a pixel circuit and a display device using the same. The pixel circuit includes a first switch element configured to connect a first node to a third node in a sampling step, a second switch element configured to supply a data voltage to a second node in the sampling step, a third switch element configured to supply a pixel driving voltage to the second node in a emission step after the sampling step, a fourth switch element configured to connect the third node to an anode of a light-emitting element in the emission step, a first capacitor connected to the first node, a second capacitor connected between the third node and the anode of the light-emitting element, and a third capacitor connected between the anode and the cathode of the light-emitting element.

Abstract: There is provided a scaffold for bone regeneration which is adapted to be implanted at a bone defect site of a bone. The scaffold comprises a main support member configured to be fixed to the bone, and a load supporting unit configured to be installed in the bone defect site of the bone to selectively bear a load applied to the bone. The load supporting unit includes one or two supporting pieces to be installed in the bone defect site of the bone to selectively bear a load applied to the bone. The supporting piece has at one end portion a contact portion to be brought into contact with and fixed to a compact bone in the bone defect site of the bone. The other end portion of the supporting piece is selectively coupled to the main support member.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer, a radiosensitizer composition for treating cancer, and a health functional food for preventing or improving cancer, which comprise N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl) benzamide, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition comprising N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl) benzamide or a derivative thereof as an active ingredient according to the present invention arrests the mitosis of cancer cells to prevent proliferation and at the same time, to exhibit low toxicity in normal cell lines and induce apoptosis only in cancer cell lines, so it can be used as an effective anticancer agent. In addition, the N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl) benzamide of the present invention can increase the sensitivity of the treated cancer cells to radiation, so it can be used as a radiosensitizer composition for cancer treatment.

Abstract: An organic light emitting display device includes a display panel including a plurality of pixels each including an organic light emitting diode, a gate driver configured to supply a gate driving signal to each of the pixels, a data driver configured to supply a data voltage to each of the pixels, a multiplexer being switched in response to an external control signal to output any one of the data voltage and a voltage supplied from a separate power supply line, and a timing controller configured to control the multiplexer to transfer the data voltage to a data line of each of the pixels in a refresh period in a low-speed driving mode and transfer the voltage from the separate power supply line to the data line of each of the pixels for at least one anode reset period in a hold period in the low-speed driving mode.

Abstract: The present invention relates to a novel Toxoplasma gondii GRA8-derived recombinant peptide, and a pharmaceutical composition and functional food for preventing or treating cancer, which includes the same as an active ingredient. The Toxoplasma gondii GRA8-derived recombinant peptide according to the present invention is a novel recombinant peptide in which a specific mitochondrial targeting sequence and an ATP5A1/SIRT3 sequence of GRA8 are conjugated to an acidity-triggered rational membrane (ATRAM), and has considerably improved efficacy in which an inhibitory concentration 50 (IC50) is improved up to 200-fold (in vitro) or 500-fold (in vivo), compared with a conventional GRA8-derived peptide (rGRA8). In addition, since the peptide treatment shows a notably distinct therapeutic effect in mouse models with cancer, the peptide may be effectively used in a pharmaceutical composition or functional food for preventing or treating cancer.

Abstract: A cover window according to an exemplary embodiment includes a glass substrate, and a first coating layer disposed on a first major surface of the glass substrate, where the first coating layer includes an epoxy silane and an oligomer, and an average molecular weight of the oligomer is about 300 g/mol to about 5000 g/mol.

Abstract: A high-frequency heating method for a hot stamping process includes: a first heating step of high-frequency heating a steel sheet, which has an aluminum (Al) coating layer formed on an iron (Fe)-based base material, to a first target temperature at a first heating rate; a second heating step of melting the coating layer by high-frequency heating the steel sheet, which has passed through the first heating step, to a second target temperature at a second heating rate, wherein the second heating rate is lower than the first heating rate; and a third heating step of high-frequency heating the steel sheet, which has passed through the second heating step, to a third target temperature at a third heating rate, wherein the third heating rate is lower than the second heating rate. A compound is formed by a reaction between a material of the coating layer and a material of the base material in the second heating step.

Abstract: A motor-driving device for varying power supplied from an external power source and supplying the varied power to a motor includes a lower base; a middle base disposed above the lower base; a cooling fan disposed between the lower base and the middle base; a connector disposed on the middle base, where the connector is electrically connected to the cooling fan; and a substrate disposed above the middle base, wherein the connector is disposed between the substrate and the middle base, wherein the connector is electrically connected to the substrate.